Neoadjuvant therapy in elderly patients receiving FOLFIRINOX or gemcitabine/nab-paclitaxel for borderline resectable or locally advanced pancreatic cancer is feasible and lead to a similar oncological outcome compared to non-aged patients - Results of the RESPECT-Study.

Maximilian Weniger; John Moir; Marko Damm; Laura Maggino; Maximilian Kordes; Jonas Rosendahl; Güralp O Ceyhan; Stephan Schorn; Falk Röder

doi:10.1016/j.suronc.2020.08.031

Neoadjuvant therapy in elderly patients receiving FOLFIRINOX or gemcitabine/nab-paclitaxel for borderline resectable or locally advanced pancreatic cancer is feasible and lead to a similar oncological outcome compared to non-aged patients - Results of the RESPECT-Study.

Maximilian Weniger, John Moir, Marko Damm, Laura Maggino, Maximilian Kordes, Jonas Rosendahl, Güralp O Ceyhan, Stephan Schorn, Falk Röder (Study group member)

Universitätsklinik für Radiotherapie und Radio-Onkologie

Publikation: Beitrag in Fachzeitschrift › Originalarbeit (Zeitschrift) › Begutachtung

7 Quellenangaben (Web of Science)

Originalsprache	Englisch
Seiten (von - bis)	285-297
Fachzeitschrift	SURGICAL ONCOLOGY
Jahrgang	35
DOIs	https://doi.org/10.1016/j.suronc.2020.08.031
Publikationsstatus	Veröffentlicht - 2020

Zugriff auf Dokument

10.1016/j.suronc.2020.08.031

Dieses zitieren

Weniger, M., Moir, J., Damm, M., Maggino, L., Kordes, M., Rosendahl, J., Ceyhan, G. O., Schorn, S., & Röder, F. (2020). Neoadjuvant therapy in elderly patients receiving FOLFIRINOX or gemcitabine/nab-paclitaxel for borderline resectable or locally advanced pancreatic cancer is feasible and lead to a similar oncological outcome compared to non-aged patients - Results of the RESPECT-Study. SURGICAL ONCOLOGY, 35, 285-297. https://doi.org/10.1016/j.suronc.2020.08.031

Weniger, Maximilian ; Moir, John ; Damm, Marko et al. / Neoadjuvant therapy in elderly patients receiving FOLFIRINOX or gemcitabine/nab-paclitaxel for borderline resectable or locally advanced pancreatic cancer is feasible and lead to a similar oncological outcome compared to non-aged patients - Results of the RESPECT-Study. in: SURGICAL ONCOLOGY. 2020 ; Jahrgang 35. S. 285-297.

@article{59073bcb639f46b6a387b4aae0789f88,

title = "Neoadjuvant therapy in elderly patients receiving FOLFIRINOX or gemcitabine/nab-paclitaxel for borderline resectable or locally advanced pancreatic cancer is feasible and lead to a similar oncological outcome compared to non-aged patients - Results of the RESPECT-Study.",

keywords = "SURVIVAL",

author = "Maximilian Weniger and John Moir and Marko Damm and Laura Maggino and Maximilian Kordes and Jonas Rosendahl and Ceyhan, {G{\"u}ralp O} and Stephan Schorn and Falk R{\"o}der",

year = "2020",

doi = "10.1016/j.suronc.2020.08.031",

language = "English",

volume = "35",

pages = "285--297",

journal = "SURGICAL ONCOLOGY",

issn = "0960-7404",

}

Weniger, M, Moir, J, Damm, M, Maggino, L, Kordes, M, Rosendahl, J, Ceyhan, GO, Schorn, S & Röder, F 2020, 'Neoadjuvant therapy in elderly patients receiving FOLFIRINOX or gemcitabine/nab-paclitaxel for borderline resectable or locally advanced pancreatic cancer is feasible and lead to a similar oncological outcome compared to non-aged patients - Results of the RESPECT-Study.', SURGICAL ONCOLOGY, Jg. 35, S. 285-297. https://doi.org/10.1016/j.suronc.2020.08.031

Neoadjuvant therapy in elderly patients receiving FOLFIRINOX or gemcitabine/nab-paclitaxel for borderline resectable or locally advanced pancreatic cancer is feasible and lead to a similar oncological outcome compared to non-aged patients - Results of the RESPECT-Study. / Weniger, Maximilian; Moir, John; Damm, Marko et al.
in: SURGICAL ONCOLOGY, Jahrgang 35, 2020, S. 285-297.

Publikation: Beitrag in Fachzeitschrift › Originalarbeit (Zeitschrift) › Begutachtung

TY - JOUR

T1 - Neoadjuvant therapy in elderly patients receiving FOLFIRINOX or gemcitabine/nab-paclitaxel for borderline resectable or locally advanced pancreatic cancer is feasible and lead to a similar oncological outcome compared to non-aged patients - Results of the RESPECT-Study.

AU - Weniger, Maximilian

AU - Moir, John

AU - Damm, Marko

AU - Maggino, Laura

AU - Kordes, Maximilian

AU - Rosendahl, Jonas

AU - Ceyhan, Güralp O

AU - Schorn, Stephan

A2 - Röder, Falk

PY - 2020

Y1 - 2020

KW - SURVIVAL

U2 - 10.1016/j.suronc.2020.08.031

DO - 10.1016/j.suronc.2020.08.031

M3 - Original Article (Journal)

C2 - 32949968

SN - 0960-7404

VL - 35

SP - 285

EP - 297

JO - SURGICAL ONCOLOGY

JF - SURGICAL ONCOLOGY

ER -

Weniger M, Moir J, Damm M, Maggino L, Kordes M, Rosendahl J et al. Neoadjuvant therapy in elderly patients receiving FOLFIRINOX or gemcitabine/nab-paclitaxel for borderline resectable or locally advanced pancreatic cancer is feasible and lead to a similar oncological outcome compared to non-aged patients - Results of the RESPECT-Study. SURGICAL ONCOLOGY. 2020;35:285-297. doi: 10.1016/j.suronc.2020.08.031